Literature DB >> 17592510

The lipoxygenase inhibitor, baicalein, modulates cell adhesion and migration by up-regulation of integrins and vinculin in rat heart endothelial cells.

Y-C S Hsieh1, S-J Hsieh, Y-S Chang, C-M Hsueh, S-L Hsu.   

Abstract

BACKGROUND AND
PURPOSE: Endothelial cell proliferation, migration and adhesion are necessary for the formation of new blood vessels. We reported previously that baicalein strongly inhibited proliferation of rat heart endothelial cells and here we assess effects on migration and adhesion of these cells. EXPERIMENTAL APPROACH: Effects of baicalein on endothelial migration and adhesion were determined by in vitro wound assays and in modified Boyden chambers. Protein expression and subcellular distribution in rat heart endothelial cells were analysed by immunoblots and immunofluorescence staining.
RESULTS: Pretreatment with baicalein for 48 h resulted in a concentration-dependent inhibition of endothelial migration, with an IC(50) of approximately 20 microM. Adhesion assays revealed that baicalein stimulated endothelial cell adhesion to fibronectin and vitronectin, effects blocked by the synthetic peptide Arg-Gly-Asp (RGD). Moreover, treatment with a blocking antibody against integrin alpha5beta1 drastically attenuated baicalein-mediated endothelial adhesion to fibronectin, but not to vitronectin. Furthermore, baicalein-mediated anti-migration effect and adhesion promotion could be partially reversed by the addition of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE). Western blot analysis indicated that baicalein increased expression levels of integrin-alpha5beta1, -alphavbeta3 and vinculin proteins. Immunofluorescence staining showed that baicalein induced a marked reorganization of actin stress fibres and the recruitment of vinculin and integrins to focal adhesion plaques, with consequently increased formation of focal adhesion contacts. CONCLUSIONS AND IMPLICATIONS: Baicalein markedly inhibited the migration and enhanced the adhesion of rat heart endothelial cells, possibly by up-regulation of the integrins (alpha5beta1 and alphavbeta3) and vinculin and by promotion of actin reorganization and focal adhesion contact formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592510      PMCID: PMC2189825          DOI: 10.1038/sj.bjp.0707345

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

Review 1.  Hepatic fibrosis: from bench to bedside.

Authors:  Detlef Schuppan; Yury Popov; Yury Porov
Journal:  J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 4.029

Review 2.  Integrins: bidirectional, allosteric signaling machines.

Authors:  Richard O Hynes
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

Review 3.  Focal adhesions: paradigm for a signaling nexus.

Authors:  Lewis H Romer; Konstantin G Birukov; Joe G N Garcia
Journal:  Circ Res       Date:  2006-03-17       Impact factor: 17.367

4.  Role of focal adhesion kinase and phosphatidylinositol 3'-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells.

Authors:  Zhao-Zhu Zeng; Yifeng Jia; Nathan J Hahn; Sonja M Markwart; Korrene F Rockwood; Donna L Livant
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

5.  Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action.

Authors:  Christian David Sadik; Helmut Sies; Tankred Schewe
Journal:  Biochem Pharmacol       Date:  2003-03-01       Impact factor: 5.858

6.  Baicalein induces a dual growth arrest by modulating multiple cell cycle regulatory molecules.

Authors:  S L Hsu; Y C Hsieh; W C Hsieh; C J Chou
Journal:  Eur J Pharmacol       Date:  2001-08-17       Impact factor: 4.432

7.  SHC-alpha5beta1 integrin interactions regulate breast cancer cell adhesion and motility.

Authors:  L Mauro; D Sisci; M Bartucci; M Salerno; J Kim; T Tam; M A Guvakova; S Ando; E Surmacz
Journal:  Exp Cell Res       Date:  1999-11-01       Impact factor: 3.905

Review 8.  Biological properties of baicalein in cardiovascular system.

Authors:  Yu Huang; Suk-Ying Tsang; Xiaoqiang Yao; Zhen-Yu Chen
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2005-04

Review 9.  Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.

Authors:  Shuang Liu
Journal:  Mol Pharm       Date:  2006 Sep-Oct       Impact factor: 4.939

10.  Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3.

Authors:  W Brian Saunders; Brenda L Bohnsack; Jennifer B Faske; Nicholas J Anthis; Kayla J Bayless; Karen K Hirschi; George E Davis
Journal:  J Cell Biol       Date:  2006-10-09       Impact factor: 10.539

View more
  4 in total

1.  Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia.

Authors:  Guang Jin; Ken Arai; Yoshihiro Murata; Sophia Wang; Monique F Stins; Eng H Lo; Klaus van Leyen
Journal:  Stroke       Date:  2008-07-17       Impact factor: 7.914

2.  Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation.

Authors:  Hsi-Hsien Hsu; Ming-Cheng Chen; Cecilia Hsuan Day; Yueh-Min Lin; Shin-Yi Li; Chuan-Chou Tu; Viswanadha Vijaya Padma; Hui-Nung Shih; Wei-Wen Kuo; Chih-Yang Huang
Journal:  World J Gastroenterol       Date:  2017-02-21       Impact factor: 5.742

3.  Baicalein 5,6-Dimethyl Ether Prevents Memory Deficits in the Scopolamine Zebrafish Model by Regulating Cholinergic and Antioxidant Systems.

Authors:  Ion Brinza; Iriny M Ayoub; Omayma A Eldahshan; Lucian Hritcu
Journal:  Plants (Basel)       Date:  2021-06-18

4.  A Chinese herbal formula "Gan-Lu-Yin" suppresses vascular smooth muscle cell migration by inhibiting matrix metalloproteinase-2/9 through the PI3K/AKT and ERK signaling pathways.

Authors:  Yi-Chung Chien; Ming-Jyh Sheu; Chieh-Hsi Wu; Wen-Hsin Lin; Ying-Yi Chen; Po-Liang Cheng; Hsu-Chen Cheng
Journal:  BMC Complement Altern Med       Date:  2012-08-24       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.